TFPI and hemophilia: Recent advances in the development of nonfactor agents with differentmechanisms of action, such as anti-TFPI antibodies (concizumab andmarstacimab) and AT siRNA (fitusiran), hold promise for providingadditional effective treatments for patients with hemophilia withinhibitors.